728 related articles for article (PubMed ID: 19215971)
1. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
[TBL] [Abstract][Full Text] [Related]
2. Monitoring aspirin therapy with the Platelet Function Analyzer-100.
Mortensen J; Poulsen TS; Grove EL; Refsgaard J; Nielsen HL; Pedersen SB; Thygesen SS; Hvas AM; Kristensen SD
Scand J Clin Lab Invest; 2008; 68(8):786-92. PubMed ID: 18651324
[TBL] [Abstract][Full Text] [Related]
3. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
[TBL] [Abstract][Full Text] [Related]
4. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
[TBL] [Abstract][Full Text] [Related]
5. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry.
Nielsen HL; Kristensen SD; Thygesen SS; Mortensen J; Pedersen SB; Grove EL; Hvas AM
Thromb Res; 2008; 123(2):267-73. PubMed ID: 18499236
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry.
Pedersen SB; Grove EL; Nielsen HL; Mortensen J; Kristensen SD; Hvas AM
Platelets; 2009 Sep; 20(6):415-20. PubMed ID: 19658002
[TBL] [Abstract][Full Text] [Related]
7. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
[TBL] [Abstract][Full Text] [Related]
8. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
Bode-Böger SM; Böger RH; Schubert M; Frölich JC
Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ
Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092
[TBL] [Abstract][Full Text] [Related]
10. Dose- and time-dependent antiplatelet effects of aspirin.
Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
[TBL] [Abstract][Full Text] [Related]
11. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.
Würtz M; Grove EL; Kristensen SD; Hvas AM
Heart; 2010 Mar; 96(5):368-71. PubMed ID: 19910291
[TBL] [Abstract][Full Text] [Related]
12. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease.
Grove EL; Hvas AM; Johnsen HL; Hedegaard SS; Pedersen SB; Mortensen J; Kristensen SD
Thromb Haemost; 2010 Jun; 103(6):1245-53. PubMed ID: 20352155
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Renda G; Tacconelli S; Capone ML; Sacchetta D; Santarelli F; Sciulli MG; Zimarino M; Grana M; D'Amelio E; Zurro M; Price TS; Patrono C; De Caterina R; Patrignani P
Clin Pharmacol Ther; 2006 Sep; 80(3):264-74. PubMed ID: 16952493
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet effect of aspirin in patients with coronary artery disease.
Grove EL
Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
17. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
Maree AO; Curtin RJ; Dooley M; Conroy RM; Crean P; Cox D; Fitzgerald DJ
J Am Coll Cardiol; 2005 Oct; 46(7):1258-63. PubMed ID: 16198840
[TBL] [Abstract][Full Text] [Related]
18. Variable platelet response to aspirin in patients with ischemic stroke.
Hohlfeld T; Weber AA; Junghans U; Schumacher M; Boucher M; Schrör K; Siebler M
Cerebrovasc Dis; 2007; 24(1):43-50. PubMed ID: 17519543
[TBL] [Abstract][Full Text] [Related]
19. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women.
Ridker PM; Hennekens CH; Tofler GH; Lipinska I; Buring JE
J Cardiovasc Risk; 1996 Apr; 3(2):209-12. PubMed ID: 8836865
[TBL] [Abstract][Full Text] [Related]
20. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]